BLUE News and Press, bluebird bio Inc. From 10/12/20

CRISPR Therapeutics is a gene-editing company founded in 2013 focused on the development and application of CRISPR/Cas9 for therapeutics. CRSP's pipeline consists of 9 therapeutics: 4 early-clinical phases targeting TDT, SCD, and immuno-oncology and 5 in the research phase. CRSP e...

Sarepta has a diversified portfolio of 43 programs including 27 gene therapy and 14 RNA programs. The pipeline is spread between discovery (21) and commercial (2) medicines. The current valuation for Sarepta is comparable to the group of 6 gene therapy companies acquired between 2017 ...

bluebird bio announces European acceptance of eli-cel gene therapy. Arena Pharmaceuticals completes enrollment for CAPTIVATE trial. Mesoblast suffers a setback as FDA rejects cell therapy application. For further details see: bluebird's European MAA, And Other News: The ...

The market's recent recovery seems to have hit a bit of a pause. After bottoming out in late March, the S&P 500 rallied by more than 50% through the end of August, only to fall by 3.9% in September. For long-term investors, though, this need not be cause for alarm. The market will a...

Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each. For further details see: These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Holders of Celgene's contingent value rights (CVRs) which pay out $9 if the FDA approves two CAR T therapies are looking at a down day after the FDA issued a CRL to Mesoblast (MESO) citing the need for an additional trial to demonstrate the efficacy of mesenchymal stem cell product Ryoncil (r...

The European Medicines Agency ((EMA)) has accepted Bluebird bio's (BLUE) marketing authorization application for its investigational elivaldogene autotemcel (eli-cel, Lenti-D) gene therapy for the treatment of patients with cerebral adrenoleukodystrophy ((CALD)), a fatal neurodegenerativ...

European Medicines Agency will evaluate eli-cel MAA under accelerated assessment bluebird bio, Inc . (Nasdaq: BLUE) today announced that the European Medicines Agency (EMA) accepted the company’s marketing authorization application (MAA) for its investigational el...

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6, at 2:00 p.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Events...